Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) Market Research Reveals Path To $8.41 Billion By 2030

Exploring the future of treatments for rare blood disorders reveals promising growth and innovation in the paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) market. As advancements in medical technology and drug development continue, this sector is poised for significant expansion, driven by evolving therapies and improved diagnostic methods.

Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome Market Size and Growth Outlook
The market for PNH and aHUS is forecasted to reach $8.42 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.1%. This upward trajectory is largely due to advancements such as next-generation complement inhibitors and enhanced diagnostic testing. Additionally, there is an increasing emphasis on developing therapies for orphan diseases, broader reimbursement policies for rare conditions, and the growing establishment of specialized hematology and nephrology treatment centers. Key trends shaping this market include rising adoption of complement inhibitor therapies, more frequent use of genetic and biomarker testing, the emergence of long-acting complement inhibition drugs, and improved early diagnosis of these complement-mediated disorders.

The paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market size has grown strongly in recent years. It will grow from $5.97 billion in 2025 to $6.41 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to limited availability of targeted complement therapies, delayed diagnosis due to disease rarity, reliance on plasma exchange and supportive care, high treatment costs restricting access, low awareness of complement-mediated disorders.

Download a free sample of the paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24357&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Primary Drivers Advancing the PNH and aHUS Market Expansion
Ongoing innovation in complement inhibitor drugs is a major catalyst propelling the PNH and aHUS market forward. These therapies specifically target parts of the immune system responsible for disease progression, offering patients more effective and tailored treatment options. The increasing availability and acceptance of such drugs have positively influenced patient outcomes and market demand.
Another significant driver is the enhanced capability to diagnose PNH and aHUS accurately through advanced genetic and biomarker testing technologies. Improved diagnostic methods enable earlier detection, facilitating timely intervention and better disease management, which in turn supports market growth. The expansion of specialized centers focusing on rare diseases also plays a crucial role by increasing patient access to expert care and innovative treatments.

Leading Corporations Shaping the Future of PNH and aHUS Therapeutics
Several key players dominate the PNH and aHUS market, including Roche Holding AG, Alexion Pharmaceuticals Inc, Genentech Inc, Novartis AG, Apellis Pharmaceuticals Inc, Omeros Corporation, BioCryst Pharmaceuticals Inc, ChemoCentryx Inc, Sanofi SA, CSL Behring, Takeda Pharmaceutical Company, Pfizer Inc, Regeneron Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Horizon Therapeutics, Achillion Pharmaceuticals Inc, Sobi Swedish Orphan Biovitrum AB, ImmunoForge Co Ltd, Care Pharma, Daiichi Sankyo Co Ltd, Astellas Pharma Inc, Mallinckrodt Pharmaceuticals, and CANbridge Pharmaceuticals Inc.
A notable collaboration took place in January 2025, when Samsung Bioepis Co. Ltd., a biopharmaceutical company based in South Korea, teamed up with Israel-based Teva Pharmaceutical Industries Ltd. This partnership aims to develop and commercialize biosimilars of Soliris (eculizumab) and EPYSQLI (eculizumab-aagh), enhancing affordable treatment access for U.S. patients suffering from these rare disorders.

View the full paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) market report:
https://www.thebusinessresearchcompany.com/report/paroxysmal-nocturnal-hemoglobinuria-pnh-and-atypical-hemolytic-uremic-syndrome-ahus-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Current Trends and Emerging Opportunities in the PNH and aHUS Market
Innovative product development remains a central focus in this field, with companies prioritizing complement inhibitors to improve treatment effectiveness and patient convenience. Complement inhibitors function by blocking specific elements of the immune complement system, which plays a role in disease pathology.
For example, in December 2023, Novartis AG received FDA approval for Fabhalta (iptacopan), the first oral monotherapy designed for adults with paroxysmal nocturnal hemoglobinuria. This medication offers superior improvements in hemoglobin levels without requiring blood transfusions. By targeting Factor B in the alternative complement pathway, Fabhalta provides comprehensive control over both intravascular and extravascular hemolysis. Its oral administration represents a significant advancement by simplifying treatment regimens and enhancing patient quality of life through reduced infusion needs.

Market Segmentation Highlights Within the PNH and aHUS Sector
This market is categorized into various segments to provide detailed insights:
1) By Type: Soliris, Ultomiris
2) By Disease Type: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS)
3) By Treatment Type: Complement Inhibitors, Plasma Exchange or Infusion, Other Symptomatic Treatments
4) By Diagnosis Method: Clinical Diagnosis, Genetic Testing, Biomarker Testing
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Further breakdown includes:
- Soliris products segmented into Eculizumab for PNH, Eculizumab for aHUS, and Eculizumab biosimilars
- Ultomiris products categorized as Ravulizumab for PNH, Ravulizumab for aHUS, and Ravulizumab extended-interval dosing

These classifications help illustrate the comprehensive nature of treatment options and diagnostic approaches shaping the PNH and aHUS market landscape.

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.